Bevacizumab and hereditary haemorrhagic telangiectasia

Cruikshank, Ross P; Chern, Boris W

doi:10.5694/j.1326-5377.2011.tb02989.x

Topics

To the Editor: Hereditary haemorrhagic telangiectasia (HHT) or Osler–Weber–Rendu syndrome manifests as vascular dysplasia involving the nose, skin, lung, brain and gastrointestinal tract. It is an inherited disorder manifesting as unbalanced angiogenesis.1

Redcliffe Hospital, Brisbane, QLD.

Correspondence: rosscruikshank@yahoo.com

1. Abdalla SA, Letarte M. Hereditary haemorrhagic telangiectasia: current views on genetics and mechanisms of disease. J Med Genet 2006; 43: 97-110.
2. Sadick H, Riedel F, Naim R, et al. Patients with hereditary hemorrhagic telangiectasia have increased levels of vascular endothelial growth factor and transforming growth factor-b1 as well as high ALK1 tissue expression. Haematologica 2005; 90: 818-828.
3. Bose P, Holter J, Selby G. Bevacizumab in hereditary hemorrhagic telangiectasia. N Engl J Med 2009; 360: 2143-2144.
4. Oosting S, Nagengast W, de Vries E. More on bevacizumab in hereditary hemorrhagic telangiectasia. N Engl J Med 2009; 361: 931.
5. Mitchell A, Adams L, MacQuillan G, et al. Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasia. Liver Transpl 2008; 14: 210-213.

Online responses are no longer available. Please refer to our instructions for authors page for more information.